**Supplemental figures**

**Figure 1.**

Schematic overview of the trial design.

**Figure 2.**

Brain interstitial fluid concentrations of the cytokines (a) IL-1b, IL-6 and TNF-α and chemokine MIB-1 (b) at indicated time-points prior to and during Delta24-RGD infusion. Concentrations are expressed in pg per mL CSF. The black line is from patient 14 who received catheter placement, but no virus infusion.

**Figure 3.**

Cerebrospinal fluid levels of the chemokines IL-8, MCP-1 and MCP-4 at indicated time-points prior to, during and after Delta24-RGD infusion. Concentrations are expressed in pg per mL CSF.

**Figure 4.**

Flow cytometric evaluation of dissociated glioma material demonstrates increased relative presence of macrophages, CD4+ and CD8+ T-cells, 26 months after treatment with Delta24-RGD compared to 4 untreated gliomas.

**Figure 5.**

Low and stable lymphocyte counts in peripheral blood (PB) after oncolytic adenovirus therapy of GBM. PB absolute numbers (i.e., cells per microliter) of total B cells (CD19+), CD56+ NK cells (CD3-CD56+), CD4+ T cells (CD3+CD4+) and CD8+T cells (CD3+CD8+) in patient 1 - 15 prior to (week 0) and at 1, 2, 4 and 12 weeks after oncolytic adenovirus therapy. Values for individual patients are shown. The gray bar, normal value in 82 healthy individuals (5-95% confidence interval).

**Figure 6.**

The levels of TNF- measured in the cerebrospinal fluid are significantly correlated with the levels of Delta24-RGD viral particles in the cerebrospinal fluid (A). In a subset of these patients, termed TNF- high, TNF- levels rose above 10 pg/mL at 4 weeks after treatment (B). Kaplan-Meier survival curve of treated patients separated into TNF--high (black line) and TNF--low groups (grey line). Only long-term surviving patient 15 belongs to the TNF--high group (C).